Certolizumab inhibits radiographic progression in patients with early rheumatoid arthritis and high rheumatoid factor levels: A pooled, post-hoc analysis of the phase 3 C-EARLY and C-OPERA trials.
Josef S Smolen, Peter C Taylor, Gerd Burmester et al.
✦ AI-curated · Sources linked
In 30 seconds
This pooled, post-hoc analysis of two phase 3 randomized trials assessed radiographic progression through Week 52 in methotrexate-naïve patients with early rheumatoid arthritis, stratified by baseline rheumatoid factor (RF) level. Among patients receiving certolizumab pegol plus methotrexate, clinically meaningful worsening at Week 24 (change in modified Total Sharp Score >5) was 1.0% with low RF and 0.0% with high RF, compared with 2.8% and 6.5%, respectively, with placebo plus methotrexate. The authors concluded that RF level did not adversely influence radiographic response to certolizumab.
Key findings
- At Week 24, radiographic worsening (ΔmTSS >5) occurred in 1.0% of low-RF and 0.0% of high-RF patients receiving certolizumab plus methotrexate.
- With placebo plus methotrexate, Week 24 worsening was 2.8% in low-RF and 6.5% in high-RF patients; the pattern persisted through Week 52.
- Clinical outcomes were generally favorable with placebo plus methotrexate and better with certolizumab plus methotrexate.
Why it matters
High RF is associated here with more severe baseline disease, but the analysis found no apparent adverse effect of RF level on radiographic response among patients treated with certolizumab plus methotrexate. This may help contextualize RF as a prognostic marker when interpreting treatment outcomes, while the numerical comparisons should not be treated as definitive subgroup evidence.
What to keep in mind
This was a pooled, post-hoc subgroup analysis of randomized trials; the reported subgroup comparisons are numerical, and the abstract does not provide inferential statistics for them.